Stakeholder consensus for decision making in eye-gaze control technology for children, adolescents and adults with cerebral palsy service provision: findings from a Delphi study.
Accessibility
Assistive technology
Augmentative and alternative communication
Cerebral palsy
Clinical decision-making
Disabilities
Eye-gaze control technology
Journal
BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555
Informations de publication
Date de publication:
10 Feb 2021
10 Feb 2021
Historique:
received:
18
06
2020
accepted:
25
01
2021
entrez:
11
2
2021
pubmed:
12
2
2021
medline:
14
4
2021
Statut:
epublish
Résumé
Limited research exists to guide clinical decisions about trialling, selecting, implementing and evaluating eye-gaze control technology. This paper reports on the outcomes of a Delphi study that was conducted to build international stakeholder consensus to inform decision making about trialling and implementing eye-gaze control technology with people with cerebral palsy. A three-round online Delphi survey was conducted. In Round 1, 126 stakeholders responded to questions identified through an international stakeholder Advisory Panel and systematic reviews. In Round 2, 63 respondents rated the importance of 200 statements generated by in Round 1. In Round 3, 41 respondents rated the importance of the 105 highest ranked statements retained from Round 2. Stakeholders achieved consensus on 94 of the original 200 statements. These statements related to person factors, support networks, the environment, and technical aspects to consider during assessment, trial, implementation and follow-up. Findings reinforced the importance of an individualised approach and that information gathered from the user, their support network and professionals are central when measuring outcomes. Information required to support an application for funding was obtained. This Delphi study has identified issues which are unique to eye-gaze control technology and will enhance its implementation with people with cerebral palsy.
Sections du résumé
BACKGROUND
BACKGROUND
Limited research exists to guide clinical decisions about trialling, selecting, implementing and evaluating eye-gaze control technology. This paper reports on the outcomes of a Delphi study that was conducted to build international stakeholder consensus to inform decision making about trialling and implementing eye-gaze control technology with people with cerebral palsy.
METHODS
METHODS
A three-round online Delphi survey was conducted. In Round 1, 126 stakeholders responded to questions identified through an international stakeholder Advisory Panel and systematic reviews. In Round 2, 63 respondents rated the importance of 200 statements generated by in Round 1. In Round 3, 41 respondents rated the importance of the 105 highest ranked statements retained from Round 2.
RESULTS
RESULTS
Stakeholders achieved consensus on 94 of the original 200 statements. These statements related to person factors, support networks, the environment, and technical aspects to consider during assessment, trial, implementation and follow-up. Findings reinforced the importance of an individualised approach and that information gathered from the user, their support network and professionals are central when measuring outcomes. Information required to support an application for funding was obtained.
CONCLUSION
CONCLUSIONS
This Delphi study has identified issues which are unique to eye-gaze control technology and will enhance its implementation with people with cerebral palsy.
Identifiants
pubmed: 33568101
doi: 10.1186/s12883-021-02077-z
pii: 10.1186/s12883-021-02077-z
pmc: PMC7874479
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
63Subventions
Organisme : Roger Montgomery Family Fund
ID : 00
Organisme : Perpetual Limited
ID : 00
Références
Patient. 2018 Apr;11(2):155-166
pubmed: 29030831
Res Involv Engagem. 2017 Aug 2;3:13
pubmed: 29062538
Acta Paediatr. 2013 Feb;102(2):161-6
pubmed: 23186066
Pediatr Neurol. 2014 Apr;50(4):324-8
pubmed: 24468636
Augment Altern Commun. 2012 Dec;28(4):278-88
pubmed: 23256859
J Adv Nurs. 2000 Oct;32(4):1008-15
pubmed: 11095242
Am J Occup Ther. 2007 May-Jun;61(3):355-64
pubmed: 17569393
Assist Technol. 2018;30(4):201-208
pubmed: 28471273
Stud Health Technol Inform. 2017;242:1095-1102
pubmed: 28873936
Dev Neurorehabil. 2017 Jul;20(5):301-308
pubmed: 27537982
Lang Speech Hear Serv Sch. 2001 Jan 1;32(1):51-56
pubmed: 27764437
Palliat Med. 2017 Sep;31(8):684-706
pubmed: 28190381
Dev Med Child Neurol. 2008 Oct;50(10):744-50
pubmed: 18834387
Disabil Rehabil Assist Technol. 2018 Jul;13(5):467-472
pubmed: 29741965
Int J Nurs Stud. 2001 Apr;38(2):195-200
pubmed: 11223060
Dev Neurorehabil. 2019 Feb;22(2):134-140
pubmed: 30252561
Acta Ophthalmol. 2010 Mar;88(2):163-73
pubmed: 20039847
Dev Med Child Neurol. 2011 Aug;53(8):704-10
pubmed: 21707596
Dev Neurorehabil. 2018 Nov;21(8):497-505
pubmed: 28862491
Disabil Rehabil Assist Technol. 2015 Jul;10(4):340-6
pubmed: 25342494
BMJ. 1996 Jan 13;312(7023):71-2
pubmed: 8555924
Dev Med Child Neurol. 2006 Jul;48(7):549-54
pubmed: 16780622
Dev Neurorehabil. 2020 Apr;23(3):145-159
pubmed: 30987518
Res Dev Disabil. 2013 Oct;34(10):3202-10
pubmed: 23891732
Am J Speech Lang Pathol. 2017 Nov 8;26(4):1225-1235
pubmed: 29086797
Disabil Rehabil Assist Technol. 2018 Jul;13(5):437-444
pubmed: 29772940
Dev Med Child Neurol. 2007 Apr;49(4):246-51
pubmed: 17376133
Dev Med Child Neurol. 2016 Oct;58(10):1016-29
pubmed: 27098366
Dev Neurorehabil. 2017 Apr;20(3):129-141
pubmed: 26930111
Augment Altern Commun. 2014 Jun;30(2):106-19
pubmed: 24758526
Dev Med Child Neurol. 2016 Feb;58 Suppl 2:50-6
pubmed: 26777873
Augment Altern Commun. 2017 Mar;33(1):32-41
pubmed: 28081651
Disabil Rehabil Assist Technol. 2014 Jan;9(1):33-40
pubmed: 23924388
Nurse Res. 2017 Jun 22;25(1):10-15
pubmed: 28639525
Lang Speech Hear Serv Sch. 2006 Jan;37(1):50-60
pubmed: 16615749
J Child Neurol. 2014 Aug;29(8):1108-18
pubmed: 24820337
Health Expect. 2017 Dec;20(6):1401-1410
pubmed: 28618076
Dev Neurorehabil. 2020 Nov;23(8):548-556
pubmed: 32496837
Dev Med Child Neurol. 2020 Mar;62(3):283-289
pubmed: 32010976
Augment Altern Commun. 2015;31(4):271-84
pubmed: 26059542
J Adv Nurs. 1994 Jan;19(1):180-6
pubmed: 8138622
BMC Med Res Methodol. 2017 Mar 21;17(1):46
pubmed: 28320348
Augment Altern Commun. 2013 Dec;29(4):299-309
pubmed: 24229334
Dev Med Child Neurol. 2020 Jan;62(1):104-110
pubmed: 31180136
Augment Altern Commun. 2007;23(4):323-35
pubmed: 17852054
J Psychosoc Nurs Ment Health Serv. 2004 May;42(5):12-20
pubmed: 15182046
Assist Technol. 2016 Summer;28(2):93-102
pubmed: 26496529